Utility Menu

National Association of Pharmacy Regulatory Authorities


Main navigation

NAPRA NDS Policies

Policy for Drugs Not Reviewed

Since the establishment of the National Drug Schedules, there have been a few cases in which a manufacturer of a new non-prescription drug or deregulated drug (one that was switched from prescription to over-the-counter status) has not requested a national drug scheduling recommendation by the National Drug Scheduling Advisory Committee (NDSAC) and accordingly, a national drug schedule assignment has not been made. This may occur because, among other reasons, the manufacturer decides not to market the new non-prescription drug in Canada or is unaware of the national scheduling process.

In the absence of an NDSAC review and information to support a specific non-prescription drug status, federally deregulated and newly approved non-prescription drugs are placed in Schedule I of the national drug scheduling model and identified accordingly.

Policy for Natural Health Products

Only products that have received a market authorization or product licence from Health Canada are approved for sale in Canada. Authorized products will bear a Drug Identification Number (DIN), a Natural Product Number (NPN) or a Drug Identification Number for Homeopathic Medicine (DIN-HM). These numbers serve as a means for the public and health care professionals to know that the product is authorized to be sold on the Canadian market.

NAPRA’s National Drug Schedules (NDS) contain products with a DIN. The Background on update to NAPRA Policy for Natural Health Products explains the history of natural health products as they related to the NDS and clarifies the applicability of the NDS to products with the classification of NPN or DIN-HM.

NAPRA’s Policy for Natural Health Products

Background on update to NAPRA Policy for Natural Health Products